source
- Experts say expanding beyond rare disease markets can make ultra-rare therapies financially viableThe piece highlights that investment in ultra‑rare disease treatments remains limited, and experts argue the answer is not to focus solely on the rare condition itself. They propose that drugmaker…
- NewLimit raises $682M to pursue new class of anti-aging drugsNewLimit, a biotech startup based in South San Francisco, announced it secured $682 million in funding. The round was led by venture firms including Kleiner Perkins, Founders Fund, Dimension Capit…